Lexaria Adds Six Global Patents, Reaches 60 Granted as It Rallies Shareholders Ahead of 2026 Meeting

An update from Lexaria Bioscience ( (LEXX) ) is now available.

Lexaria Bioscience has expanded its intellectual property estate to a total of 60 granted patents worldwide after securing six new patents across key therapeutic areas and jurisdictions. The new protections cover sublingual nicotine delivery in Australia, hypertension treatment in the European Union, epilepsy treatments in Australia and the EU, and diabetes treatment in the United States, strengthening the company’s position in large markets such as Europe’s hypertension segment and reinforcing its strategic focus in areas like GLP-1–related diabetes therapies. Lexaria emphasized that these grants are critical to underpinning future commercial partnerships for its DehydraTECH platform and, in parallel, urged shareholders of record as of December 1, 2025, to vote in line with board recommendations at its January 27, 2026 annual meeting, underscoring the importance of shareholder engagement in advancing its growth strategy.

The most recent analyst rating on (LEXX) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Lexaria Bioscience stock, see the LEXX Stock Forecast page.

More about Lexaria Bioscience

Lexaria Bioscience Corp. is a drug delivery technology company focused on its patented DehydraTECH oral formulation and processing platform, which is designed to improve the way a wide variety of drugs enter the bloodstream. The technology has demonstrated the ability to increase bio-absorption, reduce side effects, and enhance delivery across the blood-brain barrier, and Lexaria supports this with in-house research capabilities and a growing global intellectual property portfolio targeting major pharmaceutical markets.

Average Trading Volume: 637,070

Technical Sentiment Signal: Sell

Current Market Cap: $18.31M

See more insights into LEXX stock on TipRanks’ Stock Analysis page.